Biphosphonates in the treatment of bone metastases;Le traitement des métastases osseuses par les biphosphonates

Medecine Nucleaire

Volumn 30, Issue 3, 2006, Pages 164-171

  Decroisette, Chantal ^a  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

Biphosphonates; Bone metastases

Indexed keywords

PAMIDRONIC ACID; SAMARIUM; ZOLEDRONIC ACID;

BONE METASTASIS; BONE NECROSIS; BONE SCINTISCANNING; EUROPE; HUMAN; JAW; NUCLEAR MEDICINE; REVIEW;

EID: 33745212686     PISSN: 09281258     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Krempien R, Niethammer AG, Harms W, Debus J. Biphosphonates and bone metastases: current status and future directions. Expert Rev Anticancer Ther 2005;5(2):295-305.
2. Coleman RE. Metastatic bone disease; clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76.
3. Clezardin P, Gligorov J, Delmas P. Mecanismes d'action des biphosphonates sur les cellules tumorales et perspectives d'utilisation dans le traitement de l'ostéolyse maligne. Rev Rhum 2000;67(1):28-36.
4. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M et al. Zoledronic acid versus placebo in the treatment of skeletal mestastases in patients with lung cancer and other solid tumors: a phase III, double blind, randomized trial - the Zoledronic Acid Lung Study Group. J Clin Oncol 2003;21(16):3150-7.
5. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al. Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94(19):1458-68.
6. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long-term follow-up of two randomized, placebo-controllled trials. Cancer 2000;88:1082-90.
7. Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003;98(5):962-9.
8. Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Lino Y et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23(15):3314-21.
9. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18Aredia Breast Cancer Study Group. J Clin Oncol 1999;17(3):846-54
10. Hortobagyi GN, Theriault RL, Porter L, Blayner D, Lipton A, Sinoff C et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996;335(24):1785-91.
11. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, Georges S et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996;334(8):488-93
12. Ross JR, Saunders Y, Edmonds PM, Patel S, Broadley KE, Johnston SR. Systematic review of role of biphosphonates on skeletal morbidity in metastatic cancer. BMJ 200;327 (7413):469.
13. Nevilles-Webbe HL, Holen I, Coleman RE. The anti-tumour activity of biphosphonates. Cancer Treat Rev 2002;28:305-19.
14. Naveau A, Naveau B. Osteonecrosis of the jaw in patients taking biphosphonates. Joint Bone Spine 2006;73(1):7-9.
15. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaw associated with cancer chemotherapy. J Oral Maxillofac Surg 2003;61:1104-7.
16. Marx RE. Pamidronate (aredia) and zoledronate (zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-8.
17. Ruggiero SL, Meherotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of biphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
18. Woo SB, Hande K, Richardson PG. Osteonecrosis of the jaw and biphosphonates. N Engl J Med 2005;353:99-102.
19. Green JR. Antitumor effects of biphosphonates. Cancer 2003;97(3 suppl.):840-47.
20. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Biphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000;82:1459-68.
21. Van der Pluijm G, Vloedgraven H, Van Beek E, Van der Wee-Pals L, Lowik C, Papapoulos S. Biphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996;98:698-705.
22. Wood J, Bonjean K, Ruetz S et al. Novel anti-angiogenic effects of the biphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-61.
23. Yaccobi S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002;116:278-90.
24. Magnetto S, Boissier S, Delmas P, Clézardin P. Additive anti-tumor activities of taxoids in combination with the biphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 1999;83:263-9.
25. Kostenuik PJ, Orr FW, Suyama K, Singh G. Increased growth rate and tumor burden of spontaneously metastatic Walker 256 cancer cells in the skeleton of biphosphonate-treated rats. Cancer Res 1993;53:5452-7.
26. Hillner B, Ingle J, Chlebowski R, Gralow J, Yee GC, Janajan NA et al. American Society of Clinical Oncology 2003 update on the role of biphosphonates and health issues in women with breast cancer. J Clin Oncol 2003;21(21):4042-57. Epub 2003 sept 08.
27. Erratum in: J Clin Oncol 2004;22(7):1351.
28. Berenson J, Hillner B, Kyle R, Anderson K, Lipton A, Yee G, Biermann J. American Society of Clinical Oncology Clinical Practice Guidelines: the role of biphosphonates in multiple myeloma. J Clin Oncol 2002;20(17):3719-36.
29. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-87.
30. Jagdev SP, Purohit P, Heatley S, Herling C, Coleman RE. Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol 2001;12:1433-8.
31. Purohit OP, Anthony C, Radstone CR, Owen J, Coleman RE. High dose intraveinous pamidronate for metastatic bone pain. Br J Cancer 1994;70:554-8.
32. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD et al Zoledronic acid is supe-rior to pamidronate in the treat-ment of hypercalcemia: a pooled analysis of two randomized, con-trolled clinical trials. J Clin Oncol 2001;19:558-67.
33. Body JJ, Coleman RE, Piccart M. Use of biphosphonates in cancer patients. Cancer Treat Rev 1996;22:265-87.
34. Ernst DS, Brasher P, Hagen N, Paterson AH, MacDonald RN, Bruera E. A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J Pain Symptom Manage 1997;13:319-26.
35. Body JJ, Mancini I. Biphosphonates for cancer patients: why, how, and when? Support Care Cancer 2002;10:399-407
36. Rosen LS, Gordon DH, Kaminski M, Howell H, Belch A, Mackey J et al. Long term efficacity and safety of zoledronic acid compared with pamidronate disodium in treatment of skeletal complications in patients with advanced multiple myeloma or breast cancer: a randomized, double blind, multicenter, comparative trial. Cancer 2003;98:1735-44.
37. Lahtinen R, Laasko M, Palva I, Virkkunen P, Elomaa I. Randomized placebo controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992;340:1049-52.
38. Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA et al. Intravenous ibandronate reduces the incidence of skeltal complications in patients with breast cancer and bone metastases. Ann Oncol 2003;14:1399-405
39. Body JJ, Diel IJ, Lichinister M, Lazarev A, Pecherstorfer M, Bell R et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled Phase III studies. Br J Cancer 2004;90:1133-7.
40. Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:59-65.
41. Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H, Mouridsen HT. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 1999;246(1):67-74.
42. Tubiana-Hulin M, Beuzeboc P, Mauriac L, Barbet N, Frenay M, Monnier A et al. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer 2001;88:701-7.
43. Heidenreich A, Ohlmann CH. Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease. Expert Rev Anticancer Ther 2004;4:991-1005.
44. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and biphosphonates. N Engl J Med 2005;353:99-102.
45. Powles TJ, Paterson AHG, Kanis JA, Nevantaus A, Legault S, Pajunen M et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002;20(15):3219-24.
46. Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of randomized controlled trial. J Clin Oncol 2001;19:10-7.
47. Watt I, Hill P. Effects of acute administration of ethane hydroxydiphosphonate (EHDP) on skeletal scintigraphy with technetium-99m methylene diphosphonic acid (Tc-MDP) in the rat. Br J Radiol 1981;54:592-6.
48. Degrossi OJ, Oliveri P, Garcia del Rio H, Labriola R, Artagaveytia D, Degrossi EB. Technetium-99m APD compared with technetium-99m MDP as a bone scanning agent. J Nucl Med 1985;26:1135-9.
49. 99mTc-MDP. Nucl Med Biol 1997;24:27-33.
50. Tjalma WA, Buytaert PM, Berneman ZN. Reduction of visible bone metastases by clodronate therapy in breast cancer. Eur J Gynaecol Oncol 2001;22(3):215-6.
51. Murphy KJ, Line BR, Malfetano J. Etidronate therapy decreases the sensitivity of bone scanning with methylene diphosphonate labelled with technetium-99m. Can Assoc Radiol J 1997;48(3):199-202.
52. Hommeyer SH, Varney DM, Eary JF. Skeletal nonvisualization in a bone scan secondary to intravenous etidronate therapy. J Nucl Med 1992;33(5):748-50.
53. Chong WK, Cunningham DA. Case report: intravenous etidronate as a cause of poor uptake on bone scanning, with a review of the literature. Clin Radiol 1991;44(4):268-70.
54. Krasnow AZ, Collier BD, Isitman AT, Hellman RS, Ewey D. False-negative bone imaging due to etidronate disodium therapy? Clin Nucl Med 1988;13(4):264-7.
55. Carrasquillo JA, Whatley M, Dyer V, Figg WD, Dahut W. Alendronate does not interfere with 99m Tc-methylene diphosphonate bone scanning. J Nucl Med 2001;42(9):1359-63.
56. Pecherstorfer M, Schilling T, Janisch S, Woloszczuk W, Baumgartner G, Ziegler R, Ogris E. Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer. J Nucl Med 1993;34(7):1039-44.
57. Macro M, Bouvard G, Le Gangneux E, Colin T, Loyau G. Intravenous aminohydroxypropylidene biphosphonate does not modify 99mTc-hydroxymethylene biphosphonate bone scintigraphy. A prospective study. Rev Rhum Engl Ed 1995;62(2):99-104.
58. Barrista I. Biphosphonates and the fare up phenomenon. J Clin Oncol 1999;17:1328-9.
59. Marcus C, Saeed S, Milikotic A, Mishkin F, Pham H, Javellana T et al. Lack of effect of biphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153 EDTMP. Clin Nucl Med 2002;27:427-30.
60. Limouris GS, Triantafyllou N, Shukla SK, et al. Peripheral neuropathy in patients with osseous metastases after treatment with Re-186 HEDP/Sr-89 chloride/disodium pamidronate. J Nucl Med 1999;40(suppl):219P
61. Gerszten K, Heron DE, Brufsky AM. Concurrent biphosphonate with radionuclide for treatment of osseous metastases in breast cancer (résumé). Eur J Cancer 2002;38 (Supll3):S73.
62. EANM Procedure Guidelines for treatment of Refractory Metastatic bone Pain. Eur J Nucl Med 2003;30(3):BP7-BP11.
63. Hultborn R, Gundersen S, Ryden S, Holmberg E, Carstensen J, Wallgren UB et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. Anticancer Res 1999;19(4C):3383-92.